Sagimet Biosciences (Nasdaq: SGMT) announced 52-week results from a Phase 3 open-label extension trial of denifanstat in patients with moderate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE